This Anti-Aging Drug is Disrupting a $600 Billion Industry

Dr. Alan Kaplin, Chief Scientific Officer of MyMD, joins Cheddar Innovates to discuss how the MYMD-1 is on track to be the first FDA-approved drug to treat aging and age-related diseases.

Mar 24, 2022

More Videos

The Real Estate Bets Paying Off in 2026 Aren’t the Obvious Ones

Rich Hill of Principal Asset Management breaks down where real estate capital is flowing, what’s driving returns, and how 2026 could reshape the market.

One Trend Quietly Dominated Super Bowl 60 Ads, and It’s a Game Changer

From surprise celebrity overload to fewer influencers, USA Today's Ralphie Aversa breaks down the biggest Super Bowl 60 ads and why AI quietly stole the show.

Bob’s Discount Furniture Goes Public: What This IPO Means for the Retail Market

Carl Lukach, CFO of Bob’s Discount Furniture, shares insights on the company’s IPO, growth strategy, and what it means for the future of the furniture market.

Robotaxis Vs. New York City: Can Self-Driving Cars Survive the Toughest Streets on Earth?

Waymo eyes NYC, the hardest city for robotaxis yet. Safety, laws, unions, and public trust collide as autonomous cars push toward America’s streets.

Watch Josh Luber Unbox the Future of Collectibles Live on the NYSE Floor

Josh Luber reveals the thrill of “blind boxification” and how chance-driven collectibles are reshaping markets in real time.

Seahawks vs. Patriots: The Biggest Bets You Need to Know

BetMGM CEO Adam Greenblatt shares the hottest bets, surprising trends, and how prediction markets are changing the game.

From Social Feeds to Super Bowl: The Rise of Creator-Led Ads

Zoe Soon of IAB explains how TikTok and Instagram stars are now the real MVPs of Super Bowl advertising campaigns.

Go Fund Yourself: High-End Assets to High-Impact Giving

Vaulté Management is redefining luxury investing through tokenized real-world assets. Plus, InstantNonprofit is modernizing how nonprofits raise money.